Search

Search Constraints

You searched for: Author/Creator Xie, Wanling

Search Results

2. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. (August 2020)

5. Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma. (16th February 2022)

6. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Issue 4 (April 2019)

7. Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. Issue 1 (22nd January 2018)

8. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide–bortezomib combinations. (June 2015)

9. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma. Issue 17 (November 2015)

10. Evaluation of disease‐free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial‐level meta‐analysis. Issue 5 (19th December 2017)